These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7296526)

  • 1. Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer.
    Idle JR; Mahgoub A; Sloan TP; Smith RL; Mbanefo CO; Bababunmi EA
    Cancer Lett; 1981 Feb; 11(4):331-8. PubMed ID: 7296526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Individual difference in drug metabolism--pharmacogenetical approach].
    Nemoto N
    Gan To Kagaku Ryoho; 1982 May; 9(5):757-65. PubMed ID: 6764111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
    Meier PJ; Mueller HK; Dick B; Meyer UA
    Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylator genotype and arylamine-induced carcinogenesis.
    Hein DW
    Biochim Biophys Acta; 1988 Aug; 948(1):37-66. PubMed ID: 3293663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical carcinogens: how dangerous are low doses?
    Maugh TH
    Science; 1978 Oct; 202(4363):37-41. PubMed ID: 694517
    [No Abstract]   [Full Text] [Related]  

  • 6. Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis.
    Ritchie JC; Idle JR
    IARC Sci Publ; 1982; (39):381-94. PubMed ID: 7152615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphic oxidative metabolism of proguanil in a Nigerian population.
    Bolaji OO; Sadare IO; Babalola CP; Ogunbona FA
    Eur J Clin Pharmacol; 2002 Nov; 58(8):543-5. PubMed ID: 12451432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oxidative phenotype as a marker of individual predisposition to neoplasm induced by chemical carcinogens.
    Lutz W; Sułkowski W
    Pol J Occup Med; 1990; 3(3):257-72. PubMed ID: 2136533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired oxidation of debrisoquine in patients with perhexiline liver injury.
    Morgan MY; Reshef R; Shah RR; Oates NS; Smith RL; Sherlock S
    Gut; 1984 Oct; 25(10):1057-64. PubMed ID: 6479680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How chemicals may induce cancer.
    Sarasin A; Meunier-Rotival M
    Biomedicine; 1976 Nov; 24(5):306-16. PubMed ID: 793643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus.
    Baer AN; McAllister CB; Wilkinson GR; Woosley RL; Pincus T
    Arthritis Rheum; 1986 Jul; 29(7):843-50. PubMed ID: 3741500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9-mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine.
    Hietanen E; Malaveille C; Camus AM; Béréziat JC; Brun G; Castegnaro M; Michelon J; Idle JR; Bartsch H
    Drug Metab Dispos; 1986; 14(1):118-26. PubMed ID: 2868854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic susceptibility to toxic substances and its relationship to carcinogenesis.
    Hanke JZ
    IARC Sci Publ; 1984; (59):99-106. PubMed ID: 6336235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Environmental and chemical carcinogenesis.
    Wogan GN; Hecht SS; Felton JS; Conney AH; Loeb LA
    Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4'-methylene-bis(2-chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P-450 monooxygenases.
    Butler MA; Guengerich FP; Kadlubar FF
    Cancer Res; 1989 Jan; 49(1):25-31. PubMed ID: 2908851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debrisoquine oxidation phenotype during neuroleptic monotherapy.
    Spina E; Martines C; Caputi AP; Cobaleda J; Piñas B; Carrillo JA; Benitez J
    Eur J Clin Pharmacol; 1991; 41(5):467-70. PubMed ID: 1684751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic activation and inactivation of chemical carcinogens.
    Pelkonen O; Vähäkangas K
    J Toxicol Environ Health; 1980; 6(5-6):989-99. PubMed ID: 7463530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.